Watch adjacent · N3 · Residual lung disease
Opportunity Score: 62/100 · Evidence: Moderate
A drug for a nearby disease might close this gap first This card inherits the parent leftover’s score. It is not a second ranking.
CF-specific anti-inflammatories look empty until you count NCFB DPP1.
Not medical advice, not a recommendation to buy or sell any security, and not a claim that any opportunity should be funded.
A score or thesis. Always shown with evidence and a way to kill it.
CF-specific industry anti-inflammatories are absent; NCFB DPP1 programs are the adjacent crowding risk.
A published number with a source and a date. You can check it.
IV-treated pulmonary exacerbations fell to 12.1% (35.8% in 2009) but not to zero. Mean FEV1 is 89.1% among ages >7 and 72.8% among ages 40–49. Sixty-one lung transplants still occurred in 2024 (249 in 2019). Dornase remains 80.6% among ages ≥6.
A filter or count this project computed, such as the reviewed CF map.
After excluding NCFB programs, the reviewed CF industry anti-inflammatory map is empty of investigational crowding units. Academic anakinra and losartan are the visible CF-specific bets. N3 whitespace is scored 3, not 5, because late-stage NCFB DPP1 programs (brensocatib-class, including verducatib/BI-1291583 listed not-CF-primary) are adjacent crowding. Ensifentrine and HSK31858 stay off the map.
What we think the fact and analysis mean. Not a score yet.
Residual PEx and impaired FEV1 on HEMT may be inflammation, infection, structural damage, or all three. An empty CF-specific column is not automatically a newco if an NCFB drug can be tried in CF.
Why this leftover might be a real product question.
Exacerbations and advanced lung disease did not disappear. If residual disease is still inflammatory, and if NCFB DPP1 does not translate, a CF-specific anti-inflammatory would face an open industry map.
Why it might already be solved, or never be a new company.
Effect sizes on an HEMT background will be smaller than pre-modulator inflammation trials. Residual disease may not be treatable inflammation. If brensocatib-class DPP1 works in CF, this thesis is indication expansion, not company formation.
Reasons a skeptical reader would push back.
Assumptions the bet needs. If these fail, the thesis fails.
Residual PEx and FEV1 impairment on HEMT are inflammatory enough to treat; a CF-specific mechanism or CF trial is required because NCFB drugs do not automatically translate.
A pre-committed rule. If this happens, drop the thesis rather than talking yourself into it.
Kill if brensocatib-class DPP1 works in CF or if residual disease is mostly structural damage and infection rather than treatable inflammation.
Watch adjacent. Only pursue a CF-specific inflammation newco if NCFB drugs fail to translate and residual disease is still inflammatory.
This card inherits the parent need score. It is not a second ranking and not a funding recommendation.